Equillium (EQ) Competitors $0.33 +0.01 (+2.67%) Closing price 07/3/2025 03:20 PM EasternExtended Trading$0.33 0.00 (0.00%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. ALGS, IPA, STTK, MRSN, NBRV, KLRS, MURA, CELU, LIAN, and ITRMShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Aligos Therapeutics (ALGS), ImmunoPrecise Antibodies (IPA), Shattuck Labs (STTK), Mersana Therapeutics (MRSN), Nabriva Therapeutics (NBRV), Kalaris Therapeutics (KLRS), Mural Oncology (MURA), Celularity (CELU), LianBio (LIAN), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Its Competitors Aligos Therapeutics ImmunoPrecise Antibodies Shattuck Labs Mersana Therapeutics Nabriva Therapeutics Kalaris Therapeutics Mural Oncology Celularity LianBio Iterum Therapeutics Equillium (NASDAQ:EQ) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment. Which has preferable earnings & valuation, EQ or ALGS? Equillium has higher revenue and earnings than Aligos Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$41.10M0.28-$8.07M-$0.39-0.84Aligos Therapeutics$3.94M12.33-$131.21M-$17.51-0.45 Does the media prefer EQ or ALGS? In the previous week, Equillium's average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score. Company Overall Sentiment Equillium Neutral Aligos Therapeutics Neutral Do insiders and institutionals believe in EQ or ALGS? 27.1% of Equillium shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 31.6% of Equillium shares are owned by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, EQ or ALGS? Equillium has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Do analysts rate EQ or ALGS? Equillium currently has a consensus target price of $3.00, indicating a potential upside of 817.43%. Aligos Therapeutics has a consensus target price of $70.00, indicating a potential upside of 780.50%. Given Equillium's higher possible upside, research analysts clearly believe Equillium is more favorable than Aligos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is EQ or ALGS more profitable? Equillium has a net margin of -19.62% compared to Aligos Therapeutics' net margin of -1,628.75%. Aligos Therapeutics' return on equity of 14.67% beat Equillium's return on equity.Company Net Margins Return on Equity Return on Assets Equillium-19.62% -74.34% -46.75% Aligos Therapeutics -1,628.75%14.67%7.19% SummaryAligos Therapeutics beats Equillium on 7 of the 13 factors compared between the two stocks. Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.68M$2.88B$5.49B$9.02BDividend YieldN/A2.43%5.38%4.10%P/E Ratio-0.8421.5627.4720.28Price / Sales0.28244.81408.86121.46Price / CashN/A41.9536.6357.47Price / Book0.617.518.095.68Net Income-$8.07M-$55.05M$3.17B$248.96M7 Day Performance5.48%4.61%2.81%3.30%1 Month Performance-11.38%4.89%3.67%5.20%1 Year Performance-50.60%5.84%35.41%21.37% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium1.8642 of 5 stars$0.33+2.7%$3.00+817.4%-50.6%$11.68M$41.10M-0.8440Gap UpALGSAligos Therapeutics3.7862 of 5 stars$7.18-4.9%$70.00+874.9%-24.7%$46.16M$3.27M-0.4190IPAImmunoPrecise Antibodies1.7881 of 5 stars$0.96-4.5%$4.00+316.6%+33.5%$45.99M$24.00M-0.8380News CoverageSTTKShattuck Labs2.897 of 5 stars$1.01+5.5%$7.50+642.6%-77.4%$45.84M$4.61M-0.73100Gap UpMRSNMersana Therapeutics3.538 of 5 stars$0.34-6.9%$5.20+1,426.7%-84.2%$45.60M$40.50M-0.58150News CoverageNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070KLRSKalaris TherapeuticsN/A$2.36-1.7%N/AN/A$44.89MN/A0.00110MURAMural Oncology2.8795 of 5 stars$2.50+2.0%$13.00+420.0%-13.7%$42.31MN/A-0.33119News CoveragePositive NewsCELUCelularity0.0487 of 5 stars$2.01+14.2%N/A-34.3%$42.15M$54.22M-0.76220News CoverageGap UpLIANLianBioN/A$0.38+0.1%N/A+39.5%$41.09MN/A-0.47110ITRMIterum Therapeutics1.4532 of 5 stars$0.94-4.6%$9.00+852.8%-15.1%$39.60MN/A-0.9510 Related Companies and Tools Related Companies Aligos Therapeutics Competitors ImmunoPrecise Antibodies Competitors Shattuck Labs Competitors Mersana Therapeutics Competitors Nabriva Therapeutics Competitors Kalaris Therapeutics Competitors Mural Oncology Competitors Celularity Competitors LianBio Competitors Iterum Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EQ Stock Alerts